非奈利酮治疗2型糖尿病肾病有效性和安全性的Meta分析
【中图分类号】 R587.24 【文献标识码】 ADOI： 10.12114/j.issn.1007-9572.2024.0526
【Abstract】BackgroundFinerenone，a nonsteroidal mineralocorticoid antagonist，is anovel therapeuticagent forrenalprotectioninpatients withdiabetic kidneydisease，joiningtheranksofangiotensin-convertingenzyeinhibitorsand sodium-glucosecotransporter2inhibitorsinprovidingrenalprotectionforsuchpatients.Recently，twometa-analysesfocusing onpatientswithchronickidneydiseasehaveyieldedconflictingconclusionsregardingtheimpactoffinerenoneonthedeclineof estimatedglomerularfiltrationrate(eGFR).Inlightof this，thepresentmeta-analysisspecificalltargets thepopulation with type2diabetes，aiming tothoroughly investigatetheeficacyandsafetyoffinerenone.ObjectiveTosystematically evaluate theeficacyandsafetyoffnerenoneinpatientswithtype2diabetesandkidneydisease.MethodsAcomputerizedearchwas conductedintheCochraneLibrary ......
您现在查看是摘要页，全文长 19331 字符。